Don't 'MS' with Texas: A Continuing Education (CE) Learning Opportunity For Neurology Healthcare Providers - DMT Initiation, Monitoring and Rationale for Treatment Change
Starts On:
Wed, 05/14/2025: 12:00 AM
Ends On:
Thu, 05/14/2026: 12:00 AM
Type:
Enduring Material
Credit Hours:
1
Session Description:
This CE webinar series offered over three consecutive weeks to help you and your care team apply best practices for diagnosing MS and making treatment decisions. The first two webinars will focus on the clinical application of the latest MS diagnostic criteria, red flags to misdiagnosis, initial DMT choices and determining when a treatment change is needed. The final webinar will present case studies on diagnostic dilemmas and complex treatment decision making.
Target Audience
This activity has been designed to meet the educational needs of physicians, PAs, NPs, nursing professionals, pharmacists and other members of the healthcare team involved in the management of patients with MS.
Target Audience
This activity has been designed to meet the educational needs of physicians, PAs, NPs, nursing professionals, pharmacists and other members of the healthcare team involved in the management of patients with MS.
Learning Objectives:
Upon completing this activity, participants should be better able to:
Faculty Lead
Léorah Freeman MD, PhD
Dell Medical School at the University of Texas at Austin
Medical Director, MS And Neuroimmunology Center | Assistant Professor of Neurology and Diagnostic Medicine
Faculty Members
Diana Andino, MD
MS and Neuroimmunology at Austin Regional Clinic
Lauren Tardo, MD
UT Southwestern Medical Center
Clinical Lead, Neuroimmunology and MS Clinic
Accreditation Statement:
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Independence Care System. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
The CMSC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
The CMSC designates this activity for 1.0 contact hour of nursing continuing professional development (NCPD) (1.0 in the area of pharmacology).
Pharmacists
This knowledge-based activity (UAN JA4008165-9999-25-006-L01-P) qualifies for 1.0 contact hour (.1 CEUs) of continuing pharmacy education credit.
Certificate of Attendance for Other Healthcare Professionals
A Certificate of Attendance will be given upon completion of course requirements enabling participants to register their credit with the appropriate licensing boards or associations. Participants may apply for other accreditations using procedures established by specific organizations.
Disclosure of Financial Relationships
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC requires that individuals in a position to control the content of an accredited continuing education activity disclose all financial relationships with any ineligible company within the past 24 months. It is the policy of the CMSC to mitigate all relevant financial disclosures from planners, faculty, and other persons that can affect the content of this CE activity. CMSC seeks to ensure independence, objectivity, balance, and scientific rigor in all educational programs and to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC is committed to providing learners with high-quality CE activities that promote improvements in healthcare and not those of a commercial interest. For this activity, all relevant financial relationships have been mitigated.
Faculty Disclosures:
Diana Andino, MD has reported the following relevant financial relationships: Advisory board - consulting : Genentech, Amgen, Merk-EMD Serono, Multiple Sclerosis Association of America; Speaker: DKB Med; Speaker/Consulting: TG Therapeutics
Léorah Freeman MD, has reported the following relevant financial relationships: Advisor: Genentech, Horizon Therapeutics, Sanofi, and TG Therapeutics; Consultant: Hoffman LaRoche and Merck EMD Serono; Contracted Research: Genentech, Merck EMD Serono, Sanofi and TG Therapeutics; Speaker: Genentech, Merck EMD Serono, and Sanofi.
Lauren Tardo, MD, has reported the following relevant financial relationships: Consultant: Can Do MS; Advisory Board: EMD Serono
Staff Disclosures:
Laurie Scudder, DNP, NP, served as planner and reviewer and has disclosed no relevant financial relationships.
All other planners, reviewers and staff at the CMSC who are in a position to control content have disclosed no relevant financial relationships.
The planners, reviewers, editors, staff, or other members at Can Do Multiple Sclerosis who are in a position to control content have disclosed no relevant financial relationships.
Method of Participation/How to Receive Credit:
In order to successfully complete this activity, participants must:
Review the continuing education information, including learning objectives and author disclosures. View the video. Complete the evaluation, which is available at https://www.highmarksce.com/mscare.
Statements of Credit are awarded upon successful completion of the evaluation. There is no fee to participate in this activity.
Click here for detailed instructions on how to claim credit.
Release Date: May 14, 2025
Expiration Date: May 14, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of CMSC or any ineligible company that provided support for this activity.
Commercial Support Acknowledgment
This activity is supported by independent educational grants from EMD Serono, TG Therapeutics, Inc., and The Kathleen C. Moore Foundation.
Contact Information:
If you have any questions about this activity, please email [email protected].
- Differentiate high efficacy and moderate efficacy MS DMTs in order to better select therapies that address disease characteristics and patient preference – as initial treatment and if a treatment change is needed
- Describe how to use a shared decision-making approach for MS DMT decision making
- Explain factors that indicate a need for a change in DMT
Faculty Lead
Léorah Freeman MD, PhD
Dell Medical School at the University of Texas at Austin
Medical Director, MS And Neuroimmunology Center | Assistant Professor of Neurology and Diagnostic Medicine
Faculty Members
Diana Andino, MD
MS and Neuroimmunology at Austin Regional Clinic
Lauren Tardo, MD
UT Southwestern Medical Center
Clinical Lead, Neuroimmunology and MS Clinic
Accreditation Statement:
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Independence Care System. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
The CMSC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
The CMSC designates this activity for 1.0 contact hour of nursing continuing professional development (NCPD) (1.0 in the area of pharmacology).
Pharmacists
This knowledge-based activity (UAN JA4008165-9999-25-006-L01-P) qualifies for 1.0 contact hour (.1 CEUs) of continuing pharmacy education credit.
Certificate of Attendance for Other Healthcare Professionals
A Certificate of Attendance will be given upon completion of course requirements enabling participants to register their credit with the appropriate licensing boards or associations. Participants may apply for other accreditations using procedures established by specific organizations.
Disclosure of Financial Relationships
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC requires that individuals in a position to control the content of an accredited continuing education activity disclose all financial relationships with any ineligible company within the past 24 months. It is the policy of the CMSC to mitigate all relevant financial disclosures from planners, faculty, and other persons that can affect the content of this CE activity. CMSC seeks to ensure independence, objectivity, balance, and scientific rigor in all educational programs and to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC is committed to providing learners with high-quality CE activities that promote improvements in healthcare and not those of a commercial interest. For this activity, all relevant financial relationships have been mitigated.
Faculty Disclosures:
Diana Andino, MD has reported the following relevant financial relationships: Advisory board - consulting : Genentech, Amgen, Merk-EMD Serono, Multiple Sclerosis Association of America; Speaker: DKB Med; Speaker/Consulting: TG Therapeutics
Léorah Freeman MD, has reported the following relevant financial relationships: Advisor: Genentech, Horizon Therapeutics, Sanofi, and TG Therapeutics; Consultant: Hoffman LaRoche and Merck EMD Serono; Contracted Research: Genentech, Merck EMD Serono, Sanofi and TG Therapeutics; Speaker: Genentech, Merck EMD Serono, and Sanofi.
Lauren Tardo, MD, has reported the following relevant financial relationships: Consultant: Can Do MS; Advisory Board: EMD Serono
Staff Disclosures:
Laurie Scudder, DNP, NP, served as planner and reviewer and has disclosed no relevant financial relationships.
All other planners, reviewers and staff at the CMSC who are in a position to control content have disclosed no relevant financial relationships.
The planners, reviewers, editors, staff, or other members at Can Do Multiple Sclerosis who are in a position to control content have disclosed no relevant financial relationships.
Method of Participation/How to Receive Credit:
In order to successfully complete this activity, participants must:
Statements of Credit are awarded upon successful completion of the evaluation. There is no fee to participate in this activity.
Click here for detailed instructions on how to claim credit.
Release Date: May 14, 2025
Expiration Date: May 14, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of CMSC or any ineligible company that provided support for this activity.
Commercial Support Acknowledgment
This activity is supported by independent educational grants from EMD Serono, TG Therapeutics, Inc., and The Kathleen C. Moore Foundation.
Contact Information:
If you have any questions about this activity, please email [email protected].
Credit Types
ACPE: 1.00
CME: 1.00
Letter of Completion / IPCE: 1.00
NCPD: 1.00
NCPD - Pharmacology: 1.00
